Evidence map›Paper›PMID 38126681›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Chemical Evolution and Biological Evaluation of Natural Products for Efficient Therapy of Acute Lung Injury.

Chengcheng Fan, Zeyi Zhang, Zhencheng Lai, Yanzi Yang, Jiaming Li, Lei Liu, Siyu Chen, Xueping Hu, Huajun Zhao, Sunliang Cui

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. [Amentoflavone alleviates acute lung injury in mice by inhibiting cell pyroptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Chengcheng FanInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Zeyi ZhangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311402, China.
Zhencheng LaiInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Yanzi YangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311402, China.
Jiaming LiInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Lei LiuInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Siyu ChenInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Xueping HuInstitute of Molecular Sciences and Engineering, Institute of Frontier and Interdisciplinary Science, Shandong University, Qingdao, 266237, China.
Huajun ZhaoCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311402, China.
Sunliang CuiInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.ORCID 0000-0001-9407-5190
Zhejiang University · CNZhejiang Chinese Medical University · CNJinhua Academy of Agricultural Sciences · CNShandong University · CN

Funding

National Natural Science Foundation of China 21971222National Natural Science Foundation of China 22277106National Program for Support of Top-notch Young ProfessionalsNatural Science Foundation of Zhejiang Province LR23H300001Zhejiang Provincial Key R&D Program 2023C03118
6 · The paper itself

Abstract

Acute lung injury (ALI) is one of the most common complications in COVID-19 and also a syndrome of acute respiratory failure with high mortality rates, but lacks effective therapeutic drugs. Natural products provide inspiration and have proven to be the most valuable source for bioactive molecule discovery. In this study, the chemical evolution of the natural product Tanshinone IIA (Tan-IIA) to achieve a piperidine-fused scaffold through a synthetic route of pre-activation, multi-component reaction, and post-modification is presented. Through biological evaluation, it is pinpointed that compound 8b is a standout candidate with remarkable anti-inflammation and anti-oxidative stress properties, coupled with low toxicity. The mechanistic study unveils a multifaceted biological profile of 8b and shows that 8b is highly efficient in vivo for the treatment of ALI. Therefore, this work not only provides an effective strategy for the treatment of ALI, but also offers a distinctive natural product-inspired drug discovery.

Indexed as

Acute Lung InjuryRespiratory Distress SyndromeEvolution, ChemicalHumansOxidative Stressacute lung injuryanti-inflammatoryheterocyclemulti-component reactionnatural product

Identifiers

PMID38126681
PMCPMC10870070
OpenAlexW4390059134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.